Galmed Pharmaceuticals Ltd. (EOCN) earnings date, results and what the price requires
Nasdaq · SEC CIK 0001595353 · SEC filings checked Oct 18, 2026
Next report
Jan 5, 2027
Estimated from reporting history (125-day cycle, SEC periodic report filing dates). Not confirmed.
Last close
$2.85
Polygon.io daily close, Oct 16, 2026. End of day, not live.
Trailing diluted EPS
—
Needs four consecutive reported quarters.
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Sep 2, 2026 | — | $-2.7M | $2.86 | Filing |
| Mar 31, 2026 | — | Announced; figures arrive with the 10-Q | $-1.9M | — | — |
| Dec 31, 2025 | Mar 31, 2026 | Announced; figures arrive with the 10-Q | $-4.8M | — | Filing |
| Sep 30, 2025 | Nov 26, 2025 | — | $-1.9M | $0.33 | Filing |
| Jun 30, 2025 | Aug 28, 2025 | — | $-2.5M | $5.06 | Filing |
| Mar 31, 2025 | — | Announced; figures arrive with the 10-Q | $-1.1M | — | — |
| Dec 31, 2024 | Apr 2, 2025 | Announced; figures arrive with the 10-Q | $-3.2M | — | Filing |
| Sep 30, 2024 | — | — | $-1.9M | $2.31 | — |
What would Galmed Pharmaceuticals Ltd. have to report for its valuation to change?
Four consecutive reported quarters of diluted EPS are not available in SEC filings. The model is not shown rather than filled with assumptions.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.